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The renin-angiotensin-aldosterone system (RAAS) plays an essential role in the regulation of
plasma volume and arterial blood pressure. One of the most common diseases of the RAAS is
the autonomous production of aldosterone by the adrenal glands, caused by either bilateral
adrenal hyperplasia or an aldosterone-producing adenoma. This condition, known as primary
aldosteronism, is a treatable and often curable form of hypertension. The measurement of
plasma renin activity (PRA), as determined by radioimmunoassay for angiotensin I is essential
to the diagnosis of primary aldosteronism. However, accurate determination of PRA is often
hampered by low plasma concentrations of angiotensin I. Here, we report the use of immuno-
MALDI (iMALDI) as a highly sensitive and specific method for the absolute quantitation of
angiotensin I in plasma. iMALDI permits concentration determination by affinity-capture of
angiotensin I and a stable-isotopically labeled standard (SIS) peptide on immobilized anti-
peptide antibodies. The affinity beads are placed on the MALDI target, permitting automated
analysis of large numbers of patient samples. Pretreatment of the plasma is not required, and
this method is suitable for the accurate determination of angiotensin I in whole plasma. The
calibration curve generated using this method was linear over a 50-fold concentration range in
plasma, with a correlation coefficient of 0.984. MS/MS sequence confirmation provides
absolute specificity. The iMALDI angiotensin I assay, therefore, has the potential to be
developed into a method for determining PRA that has advantages in time, in specificity, and
in safety. (J Am Soc Mass Spectrom 2010, 21, 1680–1686) © 2010 American Society for Mass
SpectrometryHypertension is a serious and often symptomlesscondition that currently affects 1 billion peo-ple [1]. Because hypertension increases the
chance of heart attack, heart failure, stroke, and kidney
disease, it is imperative that treatable and/or curable
forms of hypertension be identified early and appropri-
ately managed. The renin-angiotensin-aldosterone sys-
tem (RAAS) plays an important role in the regulation of
aldosterone, and consequently, maintenance of arterial
pressure and development of certain hypertensive dis-
eases. This system is regulated by the proteolytic en-
zyme renin, which is released into the plasma from the
juxtaglomerular cells of the afferent arteriole of the
renal glomerulus in response to low arterial pressure,
direct adrenergic stimulation or reductions in Na or Cl–
concentrations in renal tubular fluid [2]. Renin cleaves the
decapeptide angiotensin I from angiotensinogen, an -2
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doi:10.1016/j.jasms.2010.01.024globular protein, which is then converted into an octapep-
tide, angiotensin II, principally but not exclusively by the
action of angiotensin converting enzyme (ACE). While
angiotensin I has no physiologic effects, angiotensin II is
a powerful vasoconstrictor and regulator of sodium
reabsorption and water retention, thereby increasing
blood pressure. Angiotensin II also stimulates the re-
lease of aldosterone from the adrenal gland, which
further increases sodium reabsorption and water reten-
tion. The resulting increase in arterial pressure then
signals the kidneys to decrease renin secretion.
Dysregulation of the RAAS leads to several treatable
causes of hypertension including, primary aldosteron-
ism (e.g., bilateral adrenal hyperplasia, aldosterone
producing adenoma, glucocorticoid remediable hyper-
tension), and secondary aldosteronism (e.g., renal ar-
tery stenosis). Essential to the diagnosis of these disor-
ders is the analytical determination of plasma renin
activity (PRA), which is usually determined from the
rate of enzymatic cleavage of angiotensin I from angio-
tensinogen during a fixed incubation period ranging from
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available competitive-binding radioimmunoassays (RIAs)
are widely used for the measurement of PRA for clinical
purposes. However, limitations of RIAs include a re-
quirement for the use of radioisotopes, nonlinear cali-
bration curves, narrow linear ranges, and analytical
interferences from peptides related to angiotensin I.
Mass spectrometry (MS)-based proteomics is a
highly sensitive technology that provides absolute
specificity through accurate molecular weight determi-
nation and peptide sequencing, thereby preventing
misdiagnosis, which could result from antibody cross-
reactivity. In addition, radioactive isotopes are not
required, making MS a safer option. The iMALDI
technique combines antibody affinity enrichment
with MS, resulting in the highly sensitive and specific
analysis of target molecules. Incorporation of stable-
isotopically labeled peptides as internal standards
permits absolute quantitation.
We have previously shown the application of the
iMALDI method for detection and quantitation of epi-
dermal growth factor receptor (EGFR) [3] and Fran-
cisella tularensis [4]. In this paper, we describe the
application of this technique to the quantitation of
angiotensin I in whole human plasma.
Materials and Methods
Chemicals and Reagents
Polyclonal antibodies to angiotensin I were obtained by
immunizing rabbits with angiotensin-I/albumin com-
plexes in Freund’s adjuvant [5]. Mouse monoclonal
antibodies to angiotensin I (ab54212, 1 mg/mL) were
purchased from AbCam (Cambridge, MA, USA). Mag-
netic Protein G Dynabeads (Invitrogen, Oslo, Norway)
were precipitated in the manufacturer’s detergent-
containing storage buffer with a magnet. The superna-
tant was removed, and the beads were washed in 1X PBS
to remove as much of the storage buffer as possible (three
washes in 50-L aliquots) by vortexing the beads in
buffer and removing the supernatant. A volume of
5 L of beads was used for each reaction. Antibodies
(2 L polyclonal antibody per reaction, or 1 g mono-
clonal antibody) were immobilized on Protein G Dyna-
beads in 1X PBS, pH 7.4 for 1 h at room temperature.
The antibody bead conjugation is done in batches so
that multiple analyses can be performed in parallel.
Excess antibody is removed by washing the beads in
1 PBS (three washes in 50 L 1 PBS). Beads are
resuspended in 1 PBS (5 L buffer per reaction) and
then aliquoted into the individual samples.
Angiotensin I was synthesized with a stable-isotopically
coded arginine residue (10 Da) (DRVYIHPFHL) at the
University of Victoria Genome BC Proteomics Centre,
Victoria, Canada, according to our previously described
protocols [6, 7].Sample Preparation
The human plasma used for these experiments was
provided by a donor with unknown diagnosis of arte-
rial pressure related disease. Blood was collected in a
BD Lavender EDTA tube. Plasma was separated, stored
at80 °C, and thawed at 4 °C. A 1-h incubation at 37 °C
was used to generate angiotensin I through cleavage of
angiotensinogen by renin (the angiotensin I generation
period). Note: Because angiotensin converting enzyme
(ACE) inhibitors were not added to the plasma samples
in these proof-of-concept experiments, the quantita-
tion of angiotensin I as described in this paper should
not be confused with the actual measurement of PRA
in human plasma. ACE would reduce the concentra-
tion of angiotensin I by cleaving it to angiotensin II,
so adding ACE inhibitors would be expected to
increase the level of angiotensin I in the plasma
sample. However, we recognize that although the
EDTA in the plasma collection tubes would be ex-
pected to inhibit ACE, a zinc metalloenzyme, for
accurate determination of PRA, we will need to verify
that all ACE in the sample is inhibited. In addition,
capture of the analyte by the antibody beads prevents
enzymatic cleavage of angiotensin I to angiotensin II
by steric hindrance [8].
Before direct MALDI TOF/TOF analysis of whole
human plasma, Millipore (Billerica, MA, USA) ZipTipC18
pipette tips were used to desalt and concentrate the
sample according to the manufacturer’s protocol. The
ZipTips were primed with 100% acetonitrile (10 L) by
aspirating solution into the tip and dispensing (repeated
twice). A 50% acetonitrile solution (10 L) was then
aspirated into the tip twice, followed by 10 L of 0.1%
TFA three times. Sample (10 L) was then aspirated and
dispensed for five cycles. A wash solution of 0.1% TFA
was then aspirated three times. Trapped peptides were
eluted with 10 L of MALDI matrix solution, and 1 L
was spotted onto the MALDI target.
iMALDI
In the iMALDI workflow for quantitation of angioten-
sin I (Figure 1), a stable-isotope coded version of
angiotensin I (synthesized by the UVic Genome BC
Proteomics Centre) is used as an internal standard.
Anti-peptide affinity beads are incubated with the
plasma sample and the internal standard for 1 to 18 h at
4 °C (the angiotensin I capture period) [3, 4, 7, 9–11].
Endogenous angiotensin I and the internal standard
are affinity captured from the plasma solution by the
antibody-bound beads, which are then placed onto a
MALDI 384-well plate for mass spectrometry analysis.
Plasma samples are kept at 4 °C throughout the
iMALDI workflow to prevent cleavage of angiotensino-
gen to angiotensin I by renin.
In these experiments, a 20-L aliquot of whole hu-
man plasma (non-digested) was incubated with immo-
bilized antibody beads (5 L slurry) overnight at 4 °C.
metr
1682 REID ET AL. J Am Soc Mass Spectrom 2010, 21, 1680–1686Binding capacity of the Protein G Dynabeads was
determined according to the manufacturer’s specifica-
tions, and an excess of beads was used in these iMALDI
experiments to ensure maximum binding of the anti-
body. While linearity of the assay over a higher concen-
tration range has not yet been assessed, samples may be
diluted to fall within the linear range if necessary. It is
also important to note that, because angiotensin I is
already of appropriate size for affinity capture and
MALDI analysis, digestion of the plasma is not neces-
sary. Beads were washed three times in 25 mM ammo-
nium bicarbonate (25-L aliquots), and then resus-
pended in 5 L 25 mM ammonium bicarbonate. A 1-L
aliquot of the bead slurry was spotted on the MALDI
target. The peptide was eluted from the immobilized
antibody beads on the MALDI target, with 10 mM
-cyano-4-hydroxycinnamic acid (CHCA) in 0.1% trif-
luoroacetic acid. MS and MS/MS analyses were per-
formed on an Applied Biosystems (Foster City, CA,
USA) 4800 MALDI TOF/TOF mass spectrometer.
In development of this iMALDI assay for the quan-
titation of angiotensin I, a 5-L aliquot of Protein G
Dynabead slurry was incubated with 2 L of polyclonal
rabbit anti-angiotensin antibody and 20 L of plasma.
Stable isotopically-labeled angiotensin I was spiked in
as an internal standard. The affinity beads were then
m/z
MS
m/z
MS2
Whole Plasma
Angiotensin I Generation
Period
Stable Is
Angioten
Elute & analyze
Figure 1. iMALDI workflow for angiotensin I.
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Absolute specificity is achieved by mass spectrowashed and spotted directly onto a stainless steelMALDI target for MS analysis, followed by MS/MS
analysis, which provides sequence information and
confirmation that the correct peptide has been detected
and quantitated.
To generate a calibration curve, 250 fmol SIS angio-
tensin I was spiked into each sample, and varying
amounts of unlabeled angiotensin I were added (0–2500
fmol). Unlabeled angiotensin I and SIS peptide were
captured by monoclonal antibody affinity beads using
our iMALDI method. The ratios of the unlabeled to
labeled angiotensin I ions were normalized to the signal
from the SIS peptide.
Results and Discussion
iMALDI Results
Angiotensin I in buffer. Using the iMALDI approach,
we were able to improve the limit of detection of
angiotensin I compared with direct MALDI mass spec-
trometric analysis of the peptide in solution. Figure 2a
shows the spectrum obtained from 4 fmol/L angio-
tensin I in 5% acetonitrile/0.1% TFA solution, spotted
directly on the MALDI target (4 fmol on target). In
contrast, Figure 2b shows the improved sensitivity
afforded by the iMALDI capture of angiotensin I from
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and50 L of a 50 amol/L (65 pg/mL) solution in PBS
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represents an 80-fold improvement in sensitivity of the
assay for angiotensin I by using by iMALDI (4 fmol/L
versus 50 amol/L). Figure 2c shows the MS/MS
spectrum of angiotensin I from this PBS solution, using
iMALDI enrichment. Although the ion signals are not
very intense, with a low signal to noise ratio (S/N:
8–28) in the MS/MS analysis, the strongest fragment
ions (b6, b9, and y9) are observed in a similar pattern to
that seen with MS/MS analysis of higher concentrations
Figure 2. Improved sensitivity in the detection of angiotensin I
by MALDI TOF MS provided by the iMALDI approach. (a) Four
fmol angiotensin I in 5% acetonitrile/0.1% TFA solution; (b) 2500
amol of angiotensin I in 50 uL PBS buffer was detected by iMALDI
(500 amol on target); (c) MS/MS of 500 amol/L on-target
angiotensin I.of angiotensin I. The mass accuracy of the fragment ions(20–160 ppm) also falls within the expected range for
MALDI TOF/TOF analysis of complex samples using
this instrument.
Angiotensin I in plasma. Figure 3 shows various stages
in the development of the iMALDI assay. When whole
(i.e., non-digested) human plasma from a donor patient
was analyzed directly by MALDI-TOF MS after a 1-h
angiotensin I generation period, angiotensin I (m/z 1296)
was not detected (Figure 3a, the arrow indicates the
absence of a peak at the m/z value corresponding to
angiotensin I). Whole human plasma was incubated
with Protein G Dynabeads without antibody to deter-
mine nonspecific binding of angiotensin I to the beads
(Figure 3b).
Endogenous angiotensin I was detectable (Figure
3c) using the iMALDI approach, even without an
angiotensin I generation period. As expected, a stron-
ger signal for angiotensin I was obtained after a 1-h
angiotensin I generation period at 37 °C (Figure 3d).
Specific fragment ions of angiotensin I were obtained
by performing MS/MS of the m/z 1296 ion from this
spectrum (Figure 3e). Only 20 L of plasma was used
in these experiments, and the angiotensin I capture
period was performed overnight (12–18 h) at 4 °C
with the immobilized antibody beads.
It should be noted that considerable background
signal is observed in the MS spectra shown in Figure 2b,
Figure 3b, c, and d, which is caused by the Tween
20-containing buffer that the Protein G Dynabeads are
stored in. While Tween aids in sample handling by
preventing loss of beads, which might otherwise stick to
the walls of the tube, it is detected by the mass spec-
trometer as a repeating series of peaks resulting in
background signals that can interfere with the detection
of low-abundance peptides such as angiotensin I. In
contrast, CHAPS detergent is detected as a single peak,
which can help reduce the possibility of interference
with the detection of target peptides. We have previ-
ously shown that an exchange of Tween 20 buffer with
CHAPS (0.3% CHAPS, 1 PBS) buffer helps to reduce
background noise and improves sensitivity, and a
manuscript describing this work is currently in prepa-
ration [7]. The Tween/CHAPS exchange, however,
does not result in complete removal of Tween, so the
use of detergent-free beads is preferred. Invitrogen
Dynal AS, Norway, kindly provided us with prototype
Protein G Dynabeads prepared without Tween. Figure
3f shows that even without an angiotensin I generation
period, the level of endogenous angiotensin I can be
quantitated in 20 L of whole plasma by iMALDI when
these prototype beads are used. A comparison of Figure
3b, c, and d with Figure 3f shows that by using these
Tween-free beads, the background signals are consid-
erably reduced.
The linearity of this assay was assessed by adding a
constant amount of isotopically-coded internal stan-
dard to whole human plasma, and increasing amounts
of a synthetic peptide representing the endogenous form
nt-fre
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linear from 0 to 125 fmol/L of added angiotensin I with
a correlation coefficient of 0.98 when synthetic angiotensin
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Determination of PRA
Time required. The standard method for determining
PRA measures the amount of angiotensin I produced
from 50 to 500 L [12] of plasma during a 1-h angio-
tensin generation period at 37 °C. At the same time, the
same sample is also incubated for 1 h at 4 °C to provide
a “zero” value. For samples with very low renin activ-
ities, angiotensin I generation periods of 3 or 18 h may
be required [13]. After angiotensin I is produced, it is
measured by competitive RIA, which requires a second
48- to 72-h incubation at 4 °C. The difference in the
concentration of angiotensin I in samples incubated at
37 °C and 4 °C is used to calculate PRA, expressed as
amount of angiotensin I (ng) per mL per hour.
The iMALDI protocol for the measurement of angio-
tensin I, as described in this paper, enabled the detec-
tion of endogenous levels of angiotensin I in donor
plasma samples (Figure 3c, d, and f) without a 1-h
angiotensin I generation period. Only 20 uL of plasma
was required for these experiments. In a PRA assay, it
might be possible to shorten the angiotensin I genera-
tion period by increasing the volume of plasma. After
the angiotensin generation period, the plasma is incu-
bated with immobilized antibody overnight, during
which time the anti-angiotensin I antibody binds both
the endogenous angiotensin I and the non-radioactive
SIS standard peptide (angiotensin I capture period). The
absolute amount of angiotensin I is determined by
MALDI-MS analysis, and the MALDI data acquisition
only takes 2 s per spot.
Calibration curve. Sandwich assays are not suitable for
measurement of small molecules like angiotensin I
because the analyte is not large enough to bind two
Figure 4. Quantitation of angiotensin I in plasma by iMALDI.
Standard curve showing the linear response of iMALDI to varying
levels of angiotensin I, spiked into a 20 L plasma sample. Two
hundred and fifty fmol SIS angiotensin I was spiked into each
sample, and the ratios were normalized to the signal from the SIS
peptide. The inset shows how the line can be extrapolated back to
the x-intercept, which gives the concentration of angiotensin I in
the original sample.separate antibodies. Instead, single antibody competi-tive binding assays are used, where the endogenous
analyte and a radiometrically-labeled analyte are incu-
bated together with an antibody that will bind both. The
resulting calibration curve is sigmoidal in shape,
thereby limiting the linear range of competitive binding
assays (such as PRA) by RIA.
The reported range for low to high angiotensin I
production in plasma is 0.2 ng/mL/h to 13.5 ng/mL/h,
respectively, with an average of 1.6 ng/mL/h [14]. A
1-h angiotensin I generation period would result in a
final plasma concentration of 150 to 10,400 attomol/
L. Even with our current version of the assay, which
measures the amount of angiotensin in one-fifth of the
original 20 L of plasma in each well on the MALDI
plate, the sensitivity of the iMALDI assay should be
sufficient to detect lower levels of angiotensin I, espe-
cially if detergent-free beads were used. Moreover, the
calibration curve for angiotensin I in plasma is linear
over the expected range in clinical samples, which is a
significant advantage for accurate quantitation.
Conclusions
In this paper, we demonstrate the use of iMALDI [3, 4,
7, 9–11] for the sensitive and specific quantitation of
angiotensin I in human plasma. Using iMALDI, angio-
tensin I is measurable in 20 L whole plasma even
without an angiotensin I generation period. With a 1-h
angiotensin I generation period at 37 °C the concentra-
tion of angiotensin I is increased, especially when ACE
inhibitors are included as in a typical PRA assay.
Although the measurement of angiotensin I in human
plasma as described in this paper is not an assay for
PRA, it is the essential “first step” in determining if such
an assay is feasible.
The iMALDI-based calibration curve was linear over
a 50-fold concentration range (from 0.2 to 3 ng in 20 L),
and thus already comes close to fulfilling the clinical
requirement for a linear calibration curve over a 60-fold
concentration range for angiotensin I. The linearity of
this response results from the ability to normalize the
response for angiotensin I to the response for the
constant amount of SIS angiotensin I in each sample.
Since only 20 L of plasma was used in this assay, the
limit of detection could easily be decreased by simply
incubating the affinity beads with an increased volume
of plasma, or using non-Tween-containing beads,
which would reduce the chemical background, or by
increasing the angiotensin I generation period. The
iMALDI angiotensin I assay, therefore, has the poten-
tial to improve upon the current PRA assay by
eliminating the need for radioactive labels, while
providing absolute quantitation, absolute specificity,
and high sensitivity.
We originally created the calibration curve shown in
Figure 4 to determine the linear range of detection using
iMALDI. However, this experiment is actually a form of
“standard addition,” and allows the accurate determi-
nation of angiotensin I in the original sample. This
1686 REID ET AL. J Am Soc Mass Spectrom 2010, 21, 1680–1686method could be useful for samples with very low
levels of angiotensin I, or in the unlikely event that there
happened to be an interfering background ion. The
sensitivity of the iMALDI approach and the speed of
the MALDI-MS acquisition actually makes it feasible to
perform this very accurate standard-addition assay on
every sample, simply by adding a constant amount of
SIS peptide and a series of known amounts of unlabeled
synthetic peptide to different aliquots.
It has been hypothesized that there should be a
correlation between the absolute concentrations of an-
giotensin I and angiotensin II, and PRA [15]. Because
iMALDI can easily be “multiplexed,” it should be
possible to monitor multiple analytes in the same
plasma sample. We are currently exploring the possi-
bility of multiplexing this technique by adding addi-
tional peptides that are involved in the RAAS, includ-
ing angiotensin II, to this iMALDI assay. We believe
that the high sensitivity of the iMALDI approach will
allow us to reduce the time for both incubation steps
required for functional assays of PRA, and to simply
perform measurements of the absolute quantity of
angiotensin I and angiotensin II in the plasma at a few
early time points, thereby improving time-to-result by
many hours and offering a new approach for screening
disorders of the RAAS pathway. With careful handling
of the patient samples, the use of appropriate peptidase
inhibitors, and the addition of SIS peptides and anti-
bodies for both angiotensin I and angiotensin II, the
iMALDI method may permit accurate quantitation of
both peptides. In fact, it may be possible to use a single
antibody to capture both peptides since angiotensin II is
simply a cleaved product of angiotensin I, differing by
two amino acids. We have demonstrated the co-capture
of closely-related peptides in a previous study on EGFR
[16]. In addition, in other experiments, we have ob-
served cross reactivity of this anti-angiotensin I poly-
clonal antibody with angiotensin II (data not shown).
However, angiotensin II was not detected in the exper-
iments described here, which may be a result of the
analytical sensitivity of our assay and/or degradation
of angiotensin II by peptidases. Measuring both angio-
tensin I and angiotensin II in the same sample would
allow us to determine whether a correlation between
angiotensin I and angiotensin II concentration could form
the basis for a new diagnostic assay for hypertension.
PRA assays by RIA are widely used for clinical
diagnosis of hypertension, and have been well charac-
terized to ensure accurate and precise results, including
blood collection protocols and sample handling, angio-
tensin I generation periods, optimal pH, and enzyme
kinetics. However, the current assay is less reliable for
low levels of angiotensin I, and involves significant
incubation times (“angiotensin I capture period” and
“angiotensin I generation period”). The assay also re-
sults in a sigmoidal calibration curve with a short linear
range, which limits its accuracy. When placing a new
assay for PRA into a clinical setting, such as this
iMALDI assay, current blood collection and samplehandling protocols should be followed. Additional con-
siderations before implementation of our iMALDI assay
for PRA in a clinical setting include determining the
lowest limit of detection, reproducibility, multiplexing
capabilities of multiple RAAS peptides, and validation
of the iMALDI method against current RIA protocols.
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